The Canadian Agency for Drugs and Technologies in Health (CADTH) has provided a positive recommendation for UBRELVY® (ubrogepant), a medication aimed at treating acute migraine. This decision is significant as it reflects the findings from the pivotal Phase 3 clinical trials known as ACHIEVE I and ACHIEVE II. These studies demonstrate UBRELVY's effectiveness in managing acute migraine episodes, which is an essential requirement for many adults suffering from this debilitating condition.
Migraines pose a considerable health challenge in Canada, affecting a substantial portion of the population. As a result, the CDA-AMC has recognized the increasing demand for effective migraine-specific treatment options. The positive recommendation for UBRELVY® is an important step forward, as it potentially expands the therapeutic options available for individuals who require acute relief from migraine symptoms.
This recommendation by the CDA-AMC will now be reviewed by provincial and territorial drug plans, which will make final decisions regarding reimbursement and availability of UBRELVY® across Canada. The decision will impact the lives of many Canadians who are seeking relief from the severe impacts of migraine.
Analyzed Canadian Outlets (1)
1 headline